News|Articles|November 18, 2026

Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo

Listen
0:00 / 0:00

Key Takeaways

  • Verismo’s Pack-IT license supports in vivo engineering of KIR-CAR T cells, positioning the platform for off-the-shelf delivery with potential reductions in time-to-treatment, cost, and access barriers.
  • Multi-chain KIR-CAR design aims to overcome single-chain CAR constraints, seeking durable antitumor activity with minimized off-target toxicity while Synkir-110 and Synkir-310 progress through Phase I.
SHOW MORE

Verismo Therapeutics licenses in vivo CAR T engineering technology from Stanford Medicine, while Pfizer licenses in vivo CAR-T programs from Starna Therapeutics.

A pair of licensing agreements this week pushed CAR T cell therapy into new territory, with two companies moving to engineer T cells directly inside the body rather than relying on today’s weeks-long manufacturing process.

Verismo Therapeutics licenses in vivo CAR T technology

Verismo Therapeutics entered an agreement to license the Pack-it technology enabling in vivo engineering of KIR-CAR T cells from Stanford Medicine. The agreement provides Verismo with technology from the lab of Crystal Mackall, MD, Ernest and Amelia Gallo Family professor, professor of pediatrics and medicine at Stanford Medicine, and founding director of the Stanford Center for Cancer Cell Therapy.1

The deal will allow Verismo to extend its multi-chain KIR-CAR platform into next-generation in vivo delivery of KIR-CAR T cell therapies, with the potential to reduce time-to-treatment and cost and broaden patient access over time.1 Verismo’s platform is designed to take CAR T therapy beyond the single-chain limitations of current approaches, with the potential to deliver durable anti-tumor responses while minimizing off-target toxicity. The platform is currently advancing in two Phase I clinical trials: Synkir-110 in solid tumors and Synkir-310 in B-cell malignancies.1 Both trials have generated early positive signals presented at the American Association for Cancer Research 2026 Annual Meeting.

Bryan Kim, chief executive officer and co-founder of Verismo Therapeutics, says the KIR-CAR platform is at the center of everything Verismo is building, "Our KIR-CAR platform is at the center of everything Verismo is building, designed to take CAR T beyond its current limitations by delivering a durable anti-tumor response while minimizing off-target toxicity." Kim continued, saying, "Today, KIR-CAR is advancing along the established CAR T pathway in two Phase 1 clinical trials, and adding the Pack-IT technology is intended to extend the platform into next-generation, off-the-shelf in vivo delivery, realizing the full potential of KIR-CAR to reach more patients, faster, and at lower cost."

Pfizer licenses in vivo CAR-T programs

Pfizer entered into an exclusive licensing agreement with Starna Therapeutics under which Starna is set to receive an upfront payment of $330 million and is eligible for up to $2.3 billion in milestone payments tied to development and commercial milestones, plus royalties on net sales of approved products.2

Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell programs focused on treating autoimmune diseases.2 Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology and in oncology, along with options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialize each exclusively licensed compound and product in Greater China.2 Pfizer is expected to lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in the United States, with sole and exclusive control over commercialization outside Greater China for all products.

The Pfizer-Starna deal also fits a broader pattern of large pharma licensing innovative technology out of China, as John Stanford, executive director at Incubate, told Pharmaceutical Executive, “the surge of interest in Chinese licensing is the product of two decades of deliberate investment. China had a very stated objective — not just to be a cheap supplier, but to edge into innovative industries. That investment is now paying off.”

Michael Vincent, chief inflammation and immunology officer, Pfizer, says “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short. Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches.”

Sources

  1. Verismo Therapeutics Licenses In Vivo CAR T Engineering Technology to Extend Its Novel Multi-Chain KIR-CAR Platform verismo Therapeutics November 18, 2026, https://www.prnewswire.com/news-releases/verismo-therapeutics-licenses-in-vivo-car-t-engineering-technology-to-extend-its-novel-multi-chain-kir-car-platform-302943157.html
  2. Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases Pfizer November 18, 2026, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-starna

Related to this article